Page 2 - Joni Rutter News Today

It will focus on projects that illuminate the basic biology of the adeno-associated virus, one of the most common gene-delivery vectors.

NIH experts: Rapid response to COVID-19 has 'silver lining' for tough-to-treat diseases

Four-part small-molecule cocktail can prevent cellular stress Researchers at the National Institutes of Health (NIH) have devised a four-part small-molecule cocktail that can protect stem cells called induced pluripotent stem cells (iPSCs) from stress and maintain normal stem cell structure and function. The researchers suggest that the cocktail could enhance the potential therapeutic uses of stem cells, ranging from treating diseases and conditions -- such as diabetes, Parkinsons disease and s...

Chen et al., Nature Methods Researchers at the National Institutes of Health have devised a four-part small-molecule cocktail that can protect stem cells called induced pluripotent stem cells (iPSCs) from stress and maintain normal stem cell structure and function. The researchers suggest that the cocktail could enhance the potential therapeutic uses of stem cells, ranging from treating diseases and conditions — such as diabetes, Parkinson’s disease and spinal cord injury — to genome edit...

 E-Mail Researchers at the National Institutes of Health (NIH) have devised a four-part small-molecule cocktail that can protect stem cells called induced pluripotent stem cells (iPSCs) from stress and maintain normal stem cell structure and function. The researchers suggest that the cocktail could enhance the potential therapeutic uses of stem cells, ranging from treating diseases and conditions -- such as diabetes, Parkinsons disease and spinal cord injury -- to genome editing. Human pluripo...

NIH funds large Phase 3 clinical trial to test repurposed drugs for treating COVID-19 symptoms Using an ACTIV master protocol, the trial will focus on potential interventions for mild-to-moderate illness. The National Institutes of Health will fund a large, randomized, placebo controlled Phase 3 clinical trial to test several existing prescription and over-the-counter medications for people to self-administer to treat symptoms of COVID-19. Part of the Accelerating COVID 19 Therapeutic Intervent...

Using an ACTIV master protocol, the trial will focus on potential interventions for mild-to-moderate illness. The National Institutes of Health will fund a large, randomized, placebo‑controlled Phase 3 clinical trial to test several existing prescription and over-the-counter medications for people to self-administer to treat symptoms of COVID-19. Part of the Accelerating COVID‑19 Therapeutic Interventions and Vaccines (ACTIV) public–private partnership, the ACTIV-6 trial aims to provide e...